Pemetrexed Market:Description
Pemetrexed market was valued at US$ 2,062.5 million in 2017, and is projected to exhibit a CAGR of 1.3% over the forecast period (2018–2026).
Chemotherapy drug pemetrexed, marketed by Eli Lilly and Company under the trade name Alimta, is indicated for the treatment of non-small cell lung cancer and pleural mesothelioma. Alimta is a folate analogue metabolic inhibitor that is prescribed in conjunction with other medications for a number of disorders For the initial course of treatment of individuals with locally progressed or metastatic nonsquamous non-small cell lung cancer, in addition to cisplatin (NSCLC) Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not progressed after four rounds of platinum-based first-line chemotherapy may receive it as a single agent for maintenance and treatment. After previous chemotherapy, as a single drug in the treatment of individuals with recurrent metastatic nonsquamous
To request a sample copy or view summary of this report, click the Here@ https://healthcaremarketreports.com/sample-request/pemetrexed-market/35679/
Market Insights
Our specialized reports offer information that is tailored to the unique needs of all the important stakeholders. Our reports provided with market evaluations that provide our clients with useful insights into market size, current competition, and factors. Reports also estimate the burden of common and unusual disease disorders based on prevalence and cost of care. Reports also include executive-level market blueprint and valuable ideas to help and establish effective expansion plans. Healthcare reports also provide in-depth examination of a market's research and development landscape. These data pointers and analysis provide in-depth research of pipeline product distribution by on clinical trial stage, therapeutic region, indication, and factors.
Pemetrexed Market: Segment Analysis
Global Pemetrexed Market: By Type
100mg
500mg
Global Pemetrexed Market: By Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Pemetrexed Market:key players
Eli Lilly
Abbott Laboratories
Cadila Healthcare
Eagle Pharmaceuticals
Stada Arzneimittel
Key Regions & Countries
All the regional segmentation has been studied based on recent and future trends, and the market is forecasted throughout the prediction period. The countries covered in the regional analysis of the Global Physiotherapy Devices market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Russia, Italy, Spain, Turkey, Netherlands, Switzerland, Belgium, and Rest of Europe in Europe, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, China, Japan, India, South Korea, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), and Argentina, Brazil, and Rest of South America as part of South America.
Click Here, Purchase of Research Report@ https://healthcaremarketreports.com/purchase/pemetrexed-market/35679/?license=single
FAQs
• What is the driving factor for the growth of this Market?
• How will the COVID-19 pandemic impact the demand and consumption of this Market?
• What is the major application area of this Market?
• Which geographical location is dominant in this Market?
• Which are the top industry players in this Market?
About Us
The healthcare industry is surely facing disruptions with global economies giving high importance to individual health. In this scenario, we expect our clients to get deep insights to power their innovations in the right direction. We have been keeping a close watch on the changes and modifications happening in the healthcare domain. As per our understanding, these alterations are active and unexampled.
Contact US
Healthcare Market Reports
99 WALL STREET, #2124 NEW YORK, NY 10005
sales@healthcaremarketreports.com
+1(929)-450-2887